Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) / Roche, Halozyme - LARVOL DELTA

Workforce Sustainability and Oncology Nursing Capacity: Healthcare Professionals' Perceptions of Atezolizumab SC vs IV in the Spanish IMscin002 Cohort (ESMO 2026) - No abstract available

Oncology

IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non-small-cell lung cancer and PK comparison to other approved indications. (PubMed, Ann Oncol) - P3 | "Compared with IV, atezolizumab SC demonstrated non-inferior drug exposure at Cycle 1. Efficacy, safety, and immunogenicity were similar between arms and consistent with the known profile for atezolizumab IV. Similar drug exposure and clinical outcomes following SC and IV administration support the use of atezolizumab SC as an alternative to atezolizumab IV."

Journal • Metastases • P3 data • PK/PD data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. (PubMed, JTO Clin Res Rep) - P2 | "There were no new safety findings, and switching between the administration routes was well tolerated. These results support the preference for SC formulations to reduce the treatment burden."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Workforce Sustainability and Oncology Nursing Capacity: Healthcare Professionals' Perceptions of Atezolizumab SC vs IV in the Spanish IMscin002 Cohort (ESMO 2026) - No abstract available

Oncology

IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration (IASLC-WCLC 2025) - P2, P3 | "Conclusions : No new or unexpected safety findings were observed. Longer term data support that most patients prefer atezolizumab SC versus IV, and that atezolizumab SC has similar efficacy, PROs, and a similar safety profile to atezolizumab IV."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • PD-L1

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CXCL8 • RET • ROS1

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (clinicaltrials.gov) - P3 | N=336 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2029 ➔ Sep 2032 | Initiation date: Jun 2026 ➔ Mar 2027 | Trial primary completion date: Sep 2029 ➔ Sep 2032

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bladder Cancer (NCCN)

NCCN guideline • Bladder Cancer

Roche...announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) filing for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy in stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer... (GlobeNewswire) - "The FDA has granted Priority Review and is expected to make a decision on the approval by 9 October 2026....The application is based on the landmark ATOMIC study..."

dMMR • FDA filing • MSI-H • PDUFA • Priority review • Colon Cancer • Microsatellite Instability

Comparative efficacy and safety of novel agents versus standard chemotherapy in first-line (1L) locally advanced or metastatic triple-negative breast cancer (TNBC): A systematic review and network meta-analyses. (ASCO 2026) - " Of 1,673 records identified, six trials comprising 2,409 patients met inclusion criteria.When compared with SC, Datopotamab deruxtecan (Dato-DXd) demonstrated largest relative effect size (P-score 0.80), followed by ipatasertib + SC (0.67), sacituzumab (0.64), atezolizumab + SC (0.54), and capivasertib + SC (0.35); hazard rations are summarised in table1. For our analysis, Dato-DXd demonstrated the most consistent efficacy signal, particularly for PFS. However, no novel strategy showed a statistically significant OS benefit, and ORR effects were highly heterogeneous. While ADC-based and targeted approaches show promising activity, current evidence remains exploratory, and longer follow-up and direct comparative trials are needed to guide optimal treatment selection."

Clinical • IO biomarker • Metastases • Review • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: University of Washington | Initiation date: Jun 2026 ➔ Sep 2026

Checkpoint inhibition • Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CXCL8 • RET • ROS1

Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. (PubMed, Lung Cancer) - P2, P3 | "Updated results from IMscin001 (part 2) and IMscin002 show similar efficacy, safety and drug immunogenicity for atezolizumab SC and IV. No new or unexpected safety signals were reported and switching between atezolizumab formulations was well tolerated."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Roche launched Tecentriq SC in India, reducing lung cancer immunotherapy delivery time from hours to just seven minutes. (Hindustan Times)

Launch non-US • Non Small Cell Lung Cancer

On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (FDA) - "Today, the FDA also approved Signatera CDx (Natera, Inc.) as a companion diagnostic device to select patients with MIBC after cystectomy who have ctDNA MRD for adjuvant treatment with Tecentriq or with Tecentriq Hybreza...Efficacy was evaluated in IMvigor011 (NCT04660344), a multi-center, randomized, double-blind, placebo-controlled trial enrolling 250 patients with MIBC who had radical cystectomy with lymph node dissection and in whom MRD was detected by serial ctDNA MRD evaluation of blood during the subsequent 12 months, starting at least 6 weeks after cystectomy. Patients were randomized (2:1) to receive either atezolizumab 1680 mg or placebo intravenously every four weeks."

Diagnostic • FDA approval • Bladder Cancer

7-minute cancer shot launched in India: New immunotherapy injection could change lung cancer treatment but comes at a cost (The Indian Express) - "The treatment is meant for those with non-small cell lung cancer, which accounts for a majority of the over 81,000 lung cancer cases diagnosed each year in India...The cost, however, remains very high — Rs 3.7 lakh per dose with most patients needing around six doses. That’s why the company is running a patient assistance programme called Blue Tree to lower the cost of treatment and make it more accessible to patients...The drug has also been included under the Central Government Health Scheme. 'The bio-equivalent dose needed for the subcutaneous version is higher — 1,800 mg against 1,200 mg for the intravenous versions — so there is a difference of around Rs 25,000 to Rs 30,000 between the two.'"

Launch non-US • Pricing • Non Small Cell Lung Cancer

Subcutaneous atezolizumab for the treatment of non-small cell lung cancer. (PubMed, Ther Deliv) - "Key gaps include real-world effectiveness and pharmacovigilance at scale, determinants of inter-individual SC bioavailability, optimal injection technique/site, and integration with perioperative or chemotherapy combinations. Overall, SC atezolizumab offers a clinically robust, patient-centered alternative to IV therapy."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

From intravenous to subcutaneous immunotherapy: Effects on care pathways and capacity in lung cancer day hospitals (ELCC 2026) - "Modeling indicated that treating 50% of patients via SC could free 468 hours of chair time and 149 hours of nursing time annually, enabling up to 402 additional sessions without extra resources.Conclusions Subcutaneous atezolizumab significantly improves day-hospital efficiency by reducing nurse workload, chair occupancy, and patient stay. These gains translate into increased capacity without additional investment, offering a practical solution to address organizational challenges resulting from increased immunotherapy volumes. Circuit optimization could further amplify these benefits."

Clinical • Lung Cancer • Oncology • Solid Tumor

Patient-reported outcomes for atezolizumab subcutaneous and intravenous: Results from the Spanish population included in IMscin002 (ELCC 2026) - P2 | "In terms of satisfaction, pts reported higher mean scores for SC vs. IV in overall satisfaction (78.5 vs. 69.5) and convenience (84.6 vs. 72.4).Conclusions In the Spanish IMscin002 cohort, atezolizumab SC demonstrated superior patient-reported satisfaction and convenience compared to the IV formulation, while maintaining stable HRQoL. These findings confirm that switching to SC administration does not compromise patient well-being and highlight the potential of this formulation to improve patient experience in Spanish clinical practice."

Clinical • Patient reported outcomes • Lung Cancer • Non Small Cell Lung Cancer

Subcutaneous Atezolizumab Improves Day Hospital Nursing Workload, Chair Occupancy (Cancer Nursing Today) - "A team of researchers from France conducted the study and presented their findings during the 2026 ELCC....Data were gathered from 10 day hospital units in France that specialized in managing lung cancer....The results revealed that subcutaneous monotherapy reduced day hospital stay times and chair times by 36.7% and 48.7%, respectively. 'Greater gains' were seen in 'optimized centers' and in institutions with a 'dedicated subcutaneous circuit.' Reductions were also observed in active nurse time (35.9%) and patient setup time; consumable costs were reduced by 71%."

Retrospective data • Non Small Cell Lung Cancer

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: University of Washington | Initiation date: Mar 2026 ➔ Jun 2026

Checkpoint inhibition • Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CXCL8 • RET • ROS1

Real-World Time, Wastage & Efficiency Impacts of Subcutaneous vs. Intravenous Atezolizumab at The Clatterbridge Cancer Centre NHS Foundation Trust (BTOG 2026) - "Subcutaneous (SC) atezolizumab shortens administration time versus the intravenous (IV) form, but the real-world impact on patient SACT unit time was unknown. This study measured the impact of the IV to SC atezolizumab changeover at CCC, measuring patient SACT unit length of stay (LoS), pharmacy drug wastage, and time from decision-to-treat (DTT) to treatment initiation."

Clinical • Real-world • Real-world evidence • Oncology

Pharmacokinetic insights into atezolizumab SC: viability of extended dosing intervals beyond the standard regimen. (PubMed, Clin Transl Oncol) - "Our PopPK model suggests that extending SC atezolizumab dosing to 4 or 5 weeks maintains therapeutic efficacy and could serve as a clinically viable alternative to standard triweekly dosing. Longer intervals may reduce efficacy and require clinical validation."

Journal • PK/PD data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (clinicaltrials.gov) - P3 | N=336 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P3 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents. (PubMed, J Thorac Dis) - No abstract available

Checkpoint inhibition • Journal • Oncology

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: University of Southern California | Trial completion date: Jul 2025 ➔ Dec 2027 | Trial primary completion date: Jul 2025 ➔ Dec 2026 | Terminated ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1